转移性肾细胞癌患者在放疗前对卡博替尼的脑部完全缓解。
Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma.
作者信息
Uche An, Sila Chad, Tanoura Tad, Yeh James, Bhowmick Neil, Posadas Edwin, Figlin Robert, Gong Jun
机构信息
Division of Hematology/Oncology, Department of Medicine, Harbor-UCLA Medical Center, 1000 W Carson St, Torrance, CA 90509, USA.
Division of Hematology/Oncology, Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA.
出版信息
Case Rep Urol. 2019 Feb 13;2019:6769017. doi: 10.1155/2019/6769017. eCollection 2019.
Cabozantinib represents an established vascular endothelial growth factor- (VEGF-) tyrosine kinase inhibitor (TKI) in the treatment paradigm of metastatic renal cell carcinoma (mRCC). Its activity in mRCC patients with brain metastases (BMs) has been largely underreported in prospective clinical trials. We present the unique case of a heavily pretreated mRCC patient with BMs who achieved a brain complete response to cabozantinib prior to receiving radiation therapy. We end with a literature review and discussion of the biologic rationale and growing evidence supporting the intracranial activity of cabozantinib.
卡博替尼是转移性肾细胞癌（mRCC）治疗模式中一种成熟的血管内皮生长因子（VEGF）-酪氨酸激酶抑制剂（TKI）。在转移性肾细胞癌伴脑转移（BM）患者中，其活性在前瞻性临床试验中大多未得到充分报道。我们报告了1例接受过大量治疗的mRCC伴BM患者的独特病例，该患者在接受放射治疗前对卡博替尼实现了脑部完全缓解。最后，我们对支持卡博替尼颅内活性的生物学原理和越来越多的证据进行了文献综述和讨论。
Zotero 插件